Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices
Clinical Pharmacology & Therapeutics · 2024-04 · 115 (4) · 658-672
DOI: 10.1002/cpt.3053 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.10.2023. Verfasst von Nadia Terranova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Pharmacology, Merck KGaA, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Artificial Intelligence, Drug Discovery. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Recent breakthroughs in artificial intelligence (AI) and machine learning (ML) have ushered in a new era of possibilities across various scientific domains. One area where these advancements hold significant promise is model‐informed drug discovery and development (MID3). To foster a wider adoption and acceptance of these advanced algorithms, the Innovation and Quality (IQ) Consortium initiated the AI/ML working group in 2021 with the aim of promoting their acceptance among the broader scientific community as well as by regulatory agencies. By drawing insights from workshops organized by the working group and attended by key stakeholders across the biopharma industry, academia, and regulatory agencies, this white paper provides a perspective from the IQ Consortium. The range of applications covered in this white paper encompass the following thematic topics: (i) AI/ML‐enabled Analytics for Pharmacometrics and Quantitative Systems Pharmacology (QSP) Workflows; (ii) Explainable Artificial Intelligence and its Applications in Disease Progression Modeling; (iii) Natural Language Processing (NLP) in Quantitative Pharmacology Modeling; and (iv) AI/ML Utilization in Drug Discovery. Additionally, the paper offers a set of best practices to ensure an effective and responsible use of AI, including considering the context of use, explainability and generalizability of models, and having human‐in‐the‐loop. We believe that embracing the transformative power of AI in quantitative modeling while adopting a set of good practices can unlock new opportunities for innovation, increase efficiency, and ultimately bring benefits to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Quantitative Pharmacology, Merck KGaA, Lausanne, Switzerland.
- Full Development Pharmacometrics, Novartis Pharma AG, Basel, Switzerland.
- Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
- Clinical Pharmacology and Translational Medicine, Eisai Inc., Nutley, New Jersey, USA.
- DMPK, Genentech Inc., South San Francisco, California, USA.
- Quantitative Pharmacology & Pharmacometrics, Merck & Co. Inc., Rahway, New Jersey, USA.
ORCID-Profile: Nadia Terranova, Didier Renard, Kumpal Madrasi, Thomas Tensfeldt, Pavan Vaddady, Nicholas Ellinwood, James Lu
Zitieren
APA
Terranova, N., Renard, D., Shahin, M. H., Menon, S., Cao, Y., Hop, C. E. C. A., Hayes, S., Madrasi, K., Stodtmann, S., Tensfeldt, T., Vaddady, P., Ellinwood, N., & Lu, J. (2024). Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices. Clinical Pharmacology & Therapeutics, 115(4), 658-672. https://doi.org/10.1002/cpt.3053
Vancouver
Terranova N, Renard D, Shahin MH, Menon S, Cao Y, Hop CECA, et al. Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices. Clinical Pharmacology & Therapeutics. 2024;115(4):658-672. doi:10.1002/cpt.3053
BibTeX
@article{Terranova2024,
author = {Terranova, Nadia and Renard, Didier and Shahin, Mohamed H and Menon, Sujatha and Cao, Youfang and Hop, Cornelis E C A and Hayes, Sean and Madrasi, Kumpal and Stodtmann, Sven and Tensfeldt, Thomas and Vaddady, Pavan and Ellinwood, Nicholas and Lu, James},
title = {Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {115},
number = {4},
pages = {658--672},
doi = {10.1002/cpt.3053}
}
EUVIMED